Last updated on May 2020

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation


Brief description of study

This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) effects of MAA868 in patients with atrial fibrillation (AF) or flutter at low risk of thromboembolic stroke or peripheral embolism.

Clinical Study Identifier: NCT04213807

Find a site near you

Start Over

Anthos Investigative Site

Beverly Hills, CA United States
  Connect »

Anthos Investigative Site

Wichita, KS United States
  Connect »

Anthos Investigative Site

Alexandria, LA United States
  Connect »

Anthos Investigative Site

Lansing, MI United States
  Connect »

Anthos Investigative Site

Minneapolis, MN United States
  Connect »

Anthos Investigative Site

Wynnewood, PA United States
  Connect »

Anthos Investigative Site

McKinney, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.